**Background of TGM3 Antibody**
Transglutaminase 3 (TGM3), a member of the transglutaminase enzyme family, catalyzes protein cross-linking via ε-(γ-glutamyl)lysine bonds, contributing to structural stability in tissues. Primarily expressed in epithelial cells, including the skin, hair follicles, and squamous mucosa, TGM3 plays a critical role in epidermal differentiation, barrier formation, and cornified envelope assembly. Dysregulation of TGM3 is linked to skin disorders (e.g., psoriasis, ichthyosis), certain cancers (e.g., squamous cell carcinoma), and autoimmune conditions.
TGM3 antibodies are tools used to detect and study the enzyme's expression, localization, and function in research. In diagnostics, they aid in investigating TGM3-associated pathologies. Notably, autoantibodies against TGM3 are implicated in rare autoimmune blistering diseases, such as lichen planus pemphigoides, where they disrupt epidermal adhesion. Commercial TGM3 antibodies (polyclonal or monoclonal) are applied in techniques like immunohistochemistry, Western blotting, and ELISA. Their specificity helps elucidate TGM3's role in cellular processes and disease mechanisms, offering potential therapeutic insights.
Research on TGM3 antibodies continues to expand their utility in both basic science and clinical applications.